Financing solutions for sustainable cancer control increase the availability of novel radiotherapy: a proposal from Uruguay, South America
Clicks: 2
ID: 311795
2022
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #550 of 631 articles by views in science and technology of advanced materials
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 631 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
In Uruguay, there are 15 accelerators and two high-dose-rate brachytherapy devices; hence, the country averages five or more radiation therapy machines per million people. This is similar to the situation in other countries, such as the United States, Canada, most of Western Europe, Scandinavia, New Zealand, Japan, and Australia. In the remainder of South America, in the countries surrounding Uruguay, the number of radiotherapy machines per million people is less than one in a few countries and between three and five in the other countries.
| Reference Key |
persistent_1771692637_6999e25da0f9a
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Alvaro Luongo-Céspedes |
| Journal | science and technology of advanced materials |
| Year | 2022 |
| DOI |
10.1088/978-0-7503-3075-6ch42
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.